PMV Pharmaceuticals Says Interim Phase 2 PYNNACLE Data Show 46% Overall Response Rate In 76 Evaluable TP53 Y220C Ovarian Cancer Patients, Median Duration Of Response 10.0 Months; Plans NDA Submission In Q1 2027

Loading news article.

PMV Pharmaceuticals Says Interim Phase 2 PYNNACLE Data Show 46% Overall Response Rate In 76 Evaluable TP53 Y220C Ovarian Cancer Patients, Median Duration Of Response 10.0 Months; Plans NDA Submission In Q1 2027 | WAPE

PMV Pharmaceuticals Says Interim Phase 2 PYNNACLE Data Show 46% Overall Response Rate In 76 Evaluable TP53 Y220C Ovarian Cancer Patients, Median Duration Of Response 10.0 Months; Plans NDA Submission In Q1 2027

Article summary

Related companies

Analyzed by WAPE AI.

Comments —